Purpose To develop a meropenem population pharmacokinetic model in critically ill patients
with particular focus on optimizing dosing regimens based on renal function. Methods …

Background Optimal antibiotic exposure is a vital but challenging prerequisite for achieving
clinical success in ICU patients. Objectives To develop and externally validate a population …

Background The primary objective of this study was to develop a population
pharmacokinetic model of meropenem, based on the population of critically ill adult patients …

Purpose Patients admitted to intensive care unit (ICU) with Klebsiella pneumoniae infections
are characterized by high mortality. The aims of the present study were to investigate the …

Meropenem dosing in critically ill patients with septic shock and continuous renal
replacement therapy (CRRT) is complex, with the recommended maintenance doses being …

Abstract Background Several population pharmacokinetic (PopPK) models for meropenem
dosing in ICU patients are available. It is not known to what extent these models can predict …

Background: Pharmacokinetics of meropenem differ widely in the critically ill population. It is
imperative to maintain meropenem concentrations above the inhibitory concentrations for …

Background Meropenem is a carbapenem antibiotic commonly used in critically ill patients
to treat severe infections. The available pharmacokinetic (PK) data has been mostly …

In the present study, population pharmacokinetic (PK) analysis was performed based on
meropenem data from a prospective study conducted in 114 critically ill patients with a wide …

Population pharmacokinetic analyses can be applied to predict optimized dosages for
individual patients. The aim of this study was to compare the prediction performance of the …